Molecular structure of Rosuvastatin, CAS Number: 287714-41-4
Rosuvastatin (CAS 287714-41-4)
See product citations (8)
Alternate Names:
Crestor
CAS Number:
287714-41-4
Molecular Weight:
481.54
Molecular Formula:
C22H28FN3O6S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Rosuvastatin is a compound that is extensively studied in the field of biochemistry for its action as an inhibitor of the enzyme HMG-CoA reductase. This enzyme plays a central role in the biosynthesis of cholesterol. Research on rosuvastatin often involves investigating the molecular mechanisms by which it modulates enzyme activity, and its effects on the biosynthetic pathways of lipids. The compound′s interaction with HMG-CoA reductase provides a model for understanding how small molecules can influence metabolic pathways at the molecular level. Additionally, studies involving rosuvastatin include its impact on the expression of genes related to cholesterol and lipid metabolism. It is also used as a reference compound in analytical studies to develop and validate methods for detecting and quantifying similar compounds in various matrices. Furthermore, rosuvastatin is of interest in studies focusing on the physicochemical properties of compounds within its class and the relationship of those properties to its biological activity.
Rosuvastatin (CAS 287714-41-4) References
- Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis. | Liping, Z., et al. 2018. Pak J Pharm Sci. 31: 2203-2208. PMID: 30463813
- Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations. | Zhang, L., et al. 2020. Herz. 45: 594-602. PMID: 30483816
- Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg. | Stein, B., et al. 2020. Ann Pharmacother. 54: 405-413. PMID: 31718234
- Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. | Perez-Calahorra, S., et al. 2019. Lipids Health Dis. 18: 216. PMID: 31829197
- Rosuvastatin-induced rhabdomyolysis due to medication errors. | Vodička, M., et al. 2020. Ceska Slov Farm. 69: 100-102. PMID: 32545989
- Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. | Kanukula, R., et al. 2021. Clin Pharmacokinet. 60: 165-175. PMID: 33428168
- Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting NLRP3 inflammasome activation. | Chen, A., et al. 2021. Cell Death Dis. 12: 78. PMID: 33436548
- Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities. | Zhang, X., et al. 2021. J Transl Med. 19: 62. PMID: 33568202
- Rosuvastatin revert memory impairment and anxiogenic-like effect in mice infected with the chronic ME-49 strain of Toxoplasma gondii. | Evangelista, FF., et al. 2021. PLoS One. 16: e0250079. PMID: 33857221
- Rosuvastatin exposure in female Wistar rats alters uterine contractility and do not show evident (anti)estrogenic effects. | de Barros, JWF., et al. 2022. Drug Chem Toxicol. 45: 2233-2245. PMID: 33934680
- Rosuvastatin and Colchicine combined myotoxicity: lessons to be learnt. | Sabanis, N., et al. 2021. CEN Case Rep. 10: 570-575. PMID: 34028728
- Rosuvastatin Alleviates Coronary Microembolization-Induced Cardiac Injury by Suppressing Nox2-Induced ROS Overproduction and Myocardial Apoptosis. | Cao, Y., et al. 2022. Cardiovasc Toxicol. 22: 341-351. PMID: 34997458
- Rhabdomyolysis induced by rosuvastatin combined with entecavir: a case report. | Wang, W., et al. 2022. BMC Infect Dis. 22: 365. PMID: 35410138
- Rosuvastatin and co-enzyme Q10 improve high-fat and high-fructose diet-induced metabolic syndrome in rats via ameliorating inflammatory and oxidative burden. | Fahmy, MIM., et al. 2022. Biomed Pharmacother. 153: 113526. PMID: 36076607
- Rosuvastatin promotes survival of random skin flaps through AMPK-mTOR pathway-induced autophagy. | Ye, H., et al. 2023. Int Immunopharmacol. 118: 110059. PMID: 37001384
Inhibitor of:
ABCG5, ABHD3, ACSVL3, AMAC1L2, Angptl3, apoA-II, apoAL, apoC1, ApoER2, APOL (Apolipoprotein L), apoL-VI, BBS9, C20orf79, CCDC132, Cholesterol Esterase, CYB5R1, EBPL, EG666803, Endothelial Lipase, GGPL-I, GPR87, GRAMD1A, GRAMD1B, HMG-3, HMG-4, HMGCL, HMGCLL1, ICMT, Kal1, LDL, LDLRAD3, LIMP I, LIMP III, LIP1, LIPH, MARCH (membrane associated ring-CH-type finger), MENTHO, mHMGCS, MVD, MVK, Nir2, NTCP, OATP-A, OATP1, Olr1590, Olr20, Olr208, Olr211, Olr222, Olr251, Olr418, ORP-8, PDSS2, PDZ-RhoGEF, Plb3, Raftlin-2, SDPR, SEC14L2, SEC14L4, SgK223, SKI-1, SLC22A11, SOAT2, ST7, StARD6, TM7SF2, and XKR4.Activator of:
AADACL2, ABC-A1, ABCA14, ABO Blood Group Antigens, apoB48R, apoC-II, CCM3, CYP27A1, CYP46, DHCR7, DPM1, EG435927, ELOVL1, FTα, GGTase-Iβ, Hepatic Lipase, INSIG-1, LCAT, Lewis Blood Group Antigen, Lmf1, MNS Blood Group Antigens, NR5A2, NSDHL, OATP-H, OATP-J, OATP16, Oatp2, PC-PLD4, PC7/8, PMVK, SCARA5, SEC14L3, SKI-1, SPFH1, SPPL3, TBL2, TERE1, and TMEM97.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rosuvastatin, 10 mg | sc-481834 | 10 mg | $145.00 |